Urinary Biomarkers for the Diagnosis of Cervical Cancer by Quantitative Label-free Mass Spectrometry Analysis

Due to the invasive procedure associated with Pap smears for diagnosing cervical cancer and the conservative culture of developing countries, identifying less invasive biomarkers is of great interest. Quantitative label-free mass spectrometry was performed to identify potential biomarkers in the urine samples of patients with cervical cancer. This technique was used to study the differential expression of urinary proteomes between normal individuals and cancer patients. The alterations in the levels of urinary proteomes in normal and cancer patients were analyzed by Progenesis label-free software and the results revealed that 60 proteins were upregulated while 73 proteins were downregulated in patients with cervical cancer. This method could enrich high molecular weight proteins from 100 kDa. The protein-protein interactions were obtained by Search Tool for the Retrieval of Interacting Genes/Proteins analysis and predicted the biological pathways involving various functions including cell-cell adhesion, blood coagulation, metabolic processes, stress response and the regulation of morphogenesis. Two notable upregulated urinary proteins were leucine-rich α-2-glycoprotein (LRG1) and isoform-1 of multimerin-1 (MMRN1), while the 3 notable downregulated proteins were S100 calcium-binding protein A8 (S100A8), serpin B3 (SERPINB3) and cluster of differentiation-44 antigen (CD44). The validation of these 5 proteins was performed by western blot analysis and the biomarker sensitivity of these proteins was analyzed individually and in combination with receiver operator characteristic curve (ROC) analysis. Quantitative mass spectrometry analysis may allow for the identification of urinary proteins of high molecular weight. The proteins MMRN1 and LRG1 were presented, for the first time, to be highly expressed urinary proteins in cervical cancer. ROC analysis revealed that LRG1 and SERPINB3 could be individually used, and these 5 proteins could also be combined, to detect the occurrence of cervical cancer.

Citing Articles

Advances in S100 protein family for gynecological malignancies.

Wu S, Xu J Discov Oncol. 2025; 16(1):287.

PMID: 40057924 PMC: 11891126. DOI: 10.1007/s12672-025-02028-x.

Recent progress in mass spectrometry-based urinary proteomics.

Joshi N, Garapati K, Ghose V, Kandasamy R, Pandey A Clin Proteomics. 2024; 21(1):14.

PMID: 38389064 PMC: 10885485. DOI: 10.1186/s12014-024-09462-z.

Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker discovery through proteomics approaches and exploring the role of cervical cancer stem cells.

Jafari A, Farahani M, Abdollahpour-Alitappeh M, Manzari-Tavakoli A, Yazdani M, Rezaei-Tavirani M Front Oncol. 2024; 13:1277772.

PMID: 38328436 PMC: 10847843. DOI: 10.3389/fonc.2023.1277772.

Searching for the methylation sites involved in human papillomavirus type 16 and 18‑positive women with cervical cancer.

Ma Y, Wang C, Shi M, Li M, Li L, Che T Mol Clin Oncol. 2022; 17(4):149.

PMID: 36157320 PMC: 9468798. DOI: 10.3892/mco.2022.2582.

Exploration of biomarkers for the diagnosis, treatment and prognosis of cervical cancer: a review.

Arip M, Tan L, Jayaraj R, Abdullah M, Rajagopal M, Selvaraja M Discov Oncol. 2022; 13(1):91.

PMID: 36152065 PMC: 9509511. DOI: 10.1007/s12672-022-00551-9.

References

Wobus M, Kuns R, Wolf C, Horn L, Kohler U, Sheyn I . CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells. Gynecol Oncol. 2001; 83(2):227-34. DOI: 10.1006/gyno.2001.6369. View

Ott H, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A . Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res. 2003; 63(21):7507-14. View

Apgar B, Zoschnick L, Wright Jr T . The 2001 Bethesda System terminology. Am Fam Physician. 2003; 68(10):1992-8. View

Wang J, Cai Y, Xu H, Zhao J, Xu X, Han Y . Expression of MRP14 gene is frequently down-regulated in Chinese human esophageal cancer. Cell Res. 2004; 14(1):46-53. DOI: 10.1038/sj.cr.7290201. View

Kong J, Ding F, Zhou C, Wang X, Miao X, Wu M . Loss of myeloid-related proteins 8 and myeloid-related proteins 14 expression in human esophageal squamous cell carcinoma correlates with poor differentiation. World J Gastroenterol. 2004; 10(8):1093-7. PMC: 4656340. DOI: 10.3748/wjg.v10.i8.1093. View

Linghu H, Xu X, Mei Y, Tang J, Tang L, Sun T . Response of early stage bulky cervical squamous carcinoma to preoperative adjuvant chemotherapy. Chin Med Sci J. 2004; 19(2):116-9. View

Hoffman M . Extent of radical hysterectomy: evolving emphasis. Gynecol Oncol. 2004; 94(1):1-9. DOI: 10.1016/j.ygyno.2004.05.025. View

Tugizov S, Berline J, Herrera R, Penaranda M, Nakagawa M, Palefsky J . Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex. J Virol. 2004; 79(2):1099-112. PMC: 538578. DOI: 10.1128/JVI.79.2.1099-1112.2005. View

Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L . Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005; 11(14):5146-52. DOI: 10.1158/1078-0432.CCR-05-0352. View

10.

Nakashima T, Yasumatsu R, Kuratomi Y, Masuda M, Kuwano T, Toh S . Role of squamous cell carcinoma antigen 1 expression in the invasive potential of head and neck squamous cell carcinoma. Head Neck. 2005; 28(1):24-30. DOI: 10.1002/hed.20293. View

11.

Umanzor J, Aguiluz M, Pineda C, Andrade S, Erazo M, Flores C . Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial. Gynecol Oncol. 2005; 100(1):70-5. DOI: 10.1016/j.ygyno.2005.07.132. View

12.

Goto T, Kino N, Shirai T, Fujimura M, Takahashi M, Shiromizu K . Late recurrence of invasive cervical cancer: twenty years' experience in a single cancer institute. J Obstet Gynaecol Res. 2005; 31(6):514-9. DOI: 10.1111/j.1447-0756.2005.00343.x. View

13.

Ng H, Yen M, Chao K, Chen C, Yuan C . Radical hysterectomy: past, present, and future. Eur J Gynaecol Oncol. 2006; 26(6):585-8. View

14.

Tanaka T, Kokawa K, Umesaki N . Preoperative chemotherapy with irinotecan and mitomycin for FIGO stage IIIb cervical squamous cell carcinoma: a pilot study. Eur J Gynaecol Oncol. 2006; 26(6):605-7. View

15.

Candelaria M, Garcia-Arias A, Cetina L, Duenas-Gonzalez A . Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol. 2006; 1:15. PMC: 1479830. DOI: 10.1186/1748-717X-1-15. View

16.

Kosunen A, Pirinen R, Ropponen K, Pukkila M, Kellokoski J, Virtaniemi J . CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol. 2006; 43(1):51-9. DOI: 10.1016/j.oraloncology.2006.01.003. View

17.

Vidalino L, Doria A, Quarta S, Zen M, Gatta A, Pontisso P . SERPINB3, apoptosis and autoimmunity. Autoimmun Rev. 2009; 9(2):108-12. DOI: 10.1016/j.autrev.2009.03.011. View

18.

Ito Y, Arai K, Nozawa R, Yoshida H, Hirokawa M, Fukushima M . S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma. Anticancer Res. 2009; 29(10):4157-61. View

19.

Wong J, Cagney G . An overview of label-free quantitation methods in proteomics by mass spectrometry. Methods Mol Biol. 2009; 604:273-83. DOI: 10.1007/978-1-60761-444-9_18. View

20.

Minami S, Sato Y, Matsumoto T, Kageyama T, Kawashima Y, Yoshio K . Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins. Cancer Genomics Proteomics. 2010; 7(4):181-9. View